July 18, 2018
Authored and Edited by Bonnie Fletcher Price, Ph.D.; Linda A. Wadler
On June 21, 2018, the Food and Drug Administration (FDA) withdrew its draft guidance for industry entitled “Statistical Approaches to Evaluate Analytical Similarity,” originally issued in September 2017. The draft guidance concerned advice for sponsors developing biosimilar products regarding the evaluation of analytical similarity between a proposed biosimilar product and the reference product. After consideration of public comments that addressed a range of issues potentially impacting the cost and efficiency of biosimilar development, the FDA decided to further consider the scientific and regulatory issues involved and withdrew the draft guidance.
The FDA stated that it intends to issue future draft guidance that will “reflect state-of-the art techniques in the evaluation of analytical data,” address “appropriate methods to analyze analytical data to account for potential lot-to-lot variability in the reference product,” and “focus on providing appropriate flexibility for sponsors. . . [to] spur the efficient development of biosimilars without compromising the agency’s rigorous scientific standards for evaluating marketing applications for biosimilars.”
Readers are encouraged to review the FDA’s withdrawal here.
Food and Drug Administration (FDA), FDA Guidance, Biologic License Application (BLA), abbreviated biologic license application (aBLA), Biologics Price Competition and Innovation Act (BPCIA)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Webinar
Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives
May 15, 2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.